Transgenic Model Of Heart Failure

Abstract

The present invention relates to transgenic models of heart failure and, more particularly, to transgenic animals and methods for testing the usefulness of chemical compounds in treating or preventing heart failure. A transgenic mouse was developed wherein Gsalpha is selectively overexpressed approximately three-fold in the heart. Although steady state adenylyl cyclase activities are not altered, both the percent of agonist high affinity beta-adrenergic receptors as well as the rate of catalyst activation are increased. In addition, physiological and pathological studies revealed that chronically-facilitated sympathetic stimulation causes adverse cardiac effects.


Claims
Download PDF
Document Preview
Document History
  • Publication: Dec 25, 2001
  • Application: Mar 29, 1996
    US US 62778896 A
  • Priority: Mar 29, 1996
    US US 62778896 A

Download Citation


Sign in to the Lens

Feedback